Entera Bio Ltd. Ordinary Shares
ENTXEntera Bio Ltd. (ENTX) is a biopharmaceutical company focused on developing oral biologic therapies for serious medical conditions. Leveraging its proprietary platform, the company aims to deliver biologic drugs that can be administered orally, offering potential advantages over traditional injectable treatments. Entera Bio’s pipeline includes candidates targeting osteoporosis, hormone deficiencies, and other indications, with an emphasis on improving patient compliance and convenience.
Company News
Entera Bio received positive FDA feedback on its Phase 3 protocol for EB613, an oral osteoporosis tablet based on teriparatide. The FDA accepted the company's proposed single-study registrational strategy with approximately 750 postmenopausal women, using total hip bone mineral density at 12 months as the primary endpoint. Phase 3 is expected to ...
U.S. stock futures rose on Monday following Friday's sharp sell-off, with major indices recovering from correction territory. President Trump suggested the U.S. could seize Iran's oil infrastructure while characterizing Iran's new leaders as 'very reasonable.' Markets are pricing in a 96.4% likelihood of unchanged Fed rates in April. Key movers i...
U.S. stock futures rose on Monday following Friday's sharp sell-off, with major indices recovering from correction territory. President Trump's comments about Iran's new leaders being 'very reasonable' and potential oil agreements provided some market optimism. Key movers included Palantir (partnership expansion), Rezolve AI (raised revenue outlo...
OPKO Health will report its financial results for Q4 and full year 2025 on February 26, 2026, followed by a conference call. The company has also expanded its partnership with Entera Bio to advance an oral long-acting PTH tablet for hypoparathyroidism treatment, marking the third successful program combining Entera's N-Tab platform with OPKO's pr...
OPKO Health and Entera Bio have expanded their collaboration to develop the first oral long-acting PTH analog for hypoparathyroidism treatment, aiming to file an IND application in late 2026. The companies will maintain equal 50/50 ownership and cost-sharing for this program. Additionally, they are advancing oral oxyntomodulin (dual GLP-1/glucago...
